Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F. Barlesi

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

Journal of Thoracic Oncology

English

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients From the French National Cancer Institute Registry: Radon France Study

Journal of Thoracic Oncology

English

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) With Oncogenic Driver Mutations: New Results From the Global IMMUNOTARGET Registry

Journal of Thoracic Oncology

English

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

P3.03-27 Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population From the Ongoing Unicancer SAFIR02-Lung / IFCT-1301 Trial

Journal of Thoracic Oncology

English

OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort From the AcSé Trial.

Journal of Thoracic Oncology

English

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

Journal of Thoracic Oncology

English

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

Journal of Thoracic Oncology

English

1302pdifct-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): Efficacy and Safety of Nivolumab and Post-Nivolumab Treatment in the French Expanded Access Program (EAP)

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by F. Barlesi

P1.01-66 Randomized Phase II Evaluating EGFR-TKI Associated With Anti-Estrogen in Women With Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial

OA09.06 Molecular Alterations and Estimated Indoor Radon in NSCLC Patients From the French National Cancer Institute Registry: Radon France Study

MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) With Oncogenic Driver Mutations: New Results From the Global IMMUNOTARGET Registry

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

P3.03-27 Somatic BRCA1/2 Mutations in Advanced NSCLC Patients: Description of a Sub-Population From the Ongoing Unicancer SAFIR02-Lung / IFCT-1301 Trial

OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort From the AcSé Trial.

OA05.05 Avelumab vs Docetaxel for Previously Treated Advanced NSCLC: Primary Analysis of the Phase 3 JAVELIN Lung 200 Trial

OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)

P1.01-04 Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients

1302pdifct-1502 CLINIVO: Real-Life Experience With Nivolumab in 600 Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC): Efficacy and Safety of Nivolumab and Post-Nivolumab Treatment in the French Expanded Access Program (EAP)